The acquisition gives Biogen near-term revenue, but the more important prize may be something pharma rarely gets to buy fully formed: a nephrology commercial platform.
On March 31, Biogen agreed to buy Apellis for about $5.6 billion, paying $41 a share in cash plus contingent payments tied to future Syfovre sales. The obvious reading is portfolio diversification: Biogen needs new growth as its multiple sclerosis business ages. But Biogen has been unusually explicit that the strategic prize is nephrology. Apellis does not just bring a drug; it brings sales infrastructure, specialist relationships, and commercial know-how in kidney disease that Biogen believes can support a broader franchise.
